Skip to main content

Table 1 Proviral DNA at baseline (week 0) and weeks 12, 24 and 48 after rhGH immunotherapy.

From: Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up

Proviral DNA, HIV-1 copy number/μg of total DNA
Patienta Baseline Week 12 Week 24 Week 48
1 B ND 8 ND 16
2 C 111 17 ND 46
3 C 476 853 711 625
4 B 536 452 307 220
5 A 55 46 50 52
6 A 223 359 99 93
7 C 315 150 83 238
8 B 42 83 28 57
9 B 91 103 35 56
10 C 15 1212* 750* ND
11 A 363 3926* 1830* 2277*
12 A 48 27 336* 138
Mean ± sem 206 ± 56.6 603 ± 321.3 433 ± 178.2 347 ± 199.9
Median 111 127 203 93
(Range) (15–536) (8–3926) (28–1830) (16–2277)
  1. a Randomisation group at week 12 to 24: A – placebo recipients; B – alternate day dosing; and C – twice weekly dosing. ND – Not Done. *Notable increase.
\